StockNews.com started coverage on shares of VBI Vaccines (NASDAQ:VBIV – Free Report) in a research report sent to investors on Tuesday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
VBI Vaccines Stock Performance
Shares of VBI Vaccines stock opened at $0.56 on Tuesday. VBI Vaccines has a twelve month low of $0.45 and a twelve month high of $1.36. The business has a 50-day moving average price of $0.65 and a 200 day moving average price of $0.63.
VBI Vaccines (NASDAQ:VBIV – Get Free Report) last announced its earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.02). VBI Vaccines had a negative return on equity of 525.42% and a negative net margin of 881.79%. The business had revenue of $1.21 million for the quarter, compared to analyst estimates of $2.85 million. As a group, equities analysts expect that VBI Vaccines will post -1.23 EPS for the current fiscal year.
VBI Vaccines Company Profile
VBI Vaccines Inc, a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.
Recommended Stories
- Five stocks we like better than VBI Vaccines
- Conference Calls and Individual Investors
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- Find and Profitably Trade Stocks at 52-Week Lows
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- 3 Monster Growth Stocks to Buy Now
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.